Matthew Keller
Stock Analyst at HC Wainwright & Co.
(0.35)
# 3,890
Out of 5,090 analysts
10
Total ratings
22.22%
Success rate
-11.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Keller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SXTP 60 Degrees Pharmaceuticals | Assumes: Buy | $6 | $0.97 | +516.40% | 1 | Nov 14, 2025 | |
| SNSE Sensei Biotherapeutics | Downgrades: Neutral | n/a | $9.72 | - | 1 | Oct 30, 2025 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $31 | $3.21 | +865.73% | 2 | Sep 30, 2025 | |
| FGEN FibroGen | Reiterates: Buy | $43 | $8.42 | +410.69% | 2 | Sep 24, 2025 | |
| IFRX InflaRx | Assumes: Buy | $6 | $1.06 | +466.04% | 1 | Sep 2, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $18 | $7.98 | +125.56% | 1 | Aug 26, 2025 | |
| PHIO Phio Pharmaceuticals | Reiterates: Buy | $14 | $1.31 | +968.70% | 1 | Aug 15, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Buy | $6 | $5.74 | +4.53% | 1 | Aug 14, 2025 |
60 Degrees Pharmaceuticals
Nov 14, 2025
Assumes: Buy
Price Target: $6
Current: $0.97
Upside: +516.40%
Sensei Biotherapeutics
Oct 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $9.72
Upside: -
Acurx Pharmaceuticals
Sep 30, 2025
Reiterates: Buy
Price Target: $31
Current: $3.21
Upside: +865.73%
FibroGen
Sep 24, 2025
Reiterates: Buy
Price Target: $43
Current: $8.42
Upside: +410.69%
InflaRx
Sep 2, 2025
Assumes: Buy
Price Target: $6
Current: $1.06
Upside: +466.04%
Gyre Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $18
Current: $7.98
Upside: +125.56%
Phio Pharmaceuticals
Aug 15, 2025
Reiterates: Buy
Price Target: $14
Current: $1.31
Upside: +968.70%
Galectin Therapeutics
Aug 14, 2025
Reiterates: Buy
Price Target: $6
Current: $5.74
Upside: +4.53%